Omeros (NASDAQ:OMER) Downgraded to “Sell” at StockNews.com

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Tuesday morning.

Omeros Price Performance

Shares of NASDAQ OMER opened at $3.46 on Tuesday. Omeros has a fifty-two week low of $0.92 and a fifty-two week high of $7.80. The firm’s 50-day simple moving average is $3.91 and its 200 day simple moving average is $2.96. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 10.80. The stock has a market cap of $217.53 million, a P/E ratio of 10.81 and a beta of 1.38.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OMER. Swiss National Bank grew its holdings in Omeros by 7.3% during the first quarter. Swiss National Bank now owns 140,500 shares of the biopharmaceutical company’s stock worth $844,000 after acquiring an additional 9,600 shares during the period. Bank of New York Mellon Corp grew its holdings in Omeros by 3.0% during the first quarter. Bank of New York Mellon Corp now owns 205,160 shares of the biopharmaceutical company’s stock worth $1,233,000 after acquiring an additional 5,938 shares during the period. MetLife Investment Management LLC grew its holdings in Omeros by 139.3% during the first quarter. MetLife Investment Management LLC now owns 28,967 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 16,862 shares during the period. BlackRock Inc. increased its stake in Omeros by 0.4% in the 1st quarter. BlackRock Inc. now owns 4,065,401 shares of the biopharmaceutical company’s stock worth $24,434,000 after purchasing an additional 15,373 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Omeros by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company’s stock worth $20,642,000 after purchasing an additional 76,869 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.